Phase 1 study of lenalidomide, bendamustine, and rituximab in previously untreated patients with chronic lymphocytic leukemia
暂无分享,去创建一个
D. Neuberg | P. Armand | M. Davids | D. Fisher | Jennifer R. Brown | P. Amrein | L. Werner | J. Abramson | E. Hochberg | J. Soumerai
[1] Jeffrey A Jones,et al. Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia. , 2018, Blood.
[2] I. Flinn,et al. Phase 2 CAPTIVATE results of ibrutinib (ibr) plus venetoclax (ven) in first-line chronic lymphocytic leukemia (CLL). , 2018 .
[3] J. Leonard,et al. A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin’s lymphoma (NHL): CALGB 50803 (Alliance) , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] T. Kipps,et al. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. , 2017, The Lancet. Oncology.
[5] W. Klapper,et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. , 2016, The Lancet. Oncology.
[6] Hui Liu,et al. Efficacy of lenalidomide in relapsed/refractory chronic lymphocytic leukemia patient: a systematic review and meta-analysis , 2016, Annals of Hematology.
[7] J. Gribben,et al. Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial , 2016, Blood Cancer Journal.
[8] H. Döhner,et al. Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia , 2016, European journal of haematology.
[9] H. Döhner,et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. , 2016, Blood.
[10] Scott E. Smith,et al. Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103. , 2015, Blood.
[11] Sonali M. Smith,et al. Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma. , 2015, The New England journal of medicine.
[12] M. Czuczman,et al. Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance). , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Sonali M. Smith,et al. Unexpected and Serious Toxicity Observed with Combined Idelalisib, Lenalidomide and Rituximab in Relapsed/Refractory B Cell Lymphomas: Alliance A051201 and A051202 , 2014 .
[14] Michael L. Wang,et al. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. , 2014, The Lancet. Oncology.
[15] Andrew W. Greaves,et al. Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Michael L. Wang,et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial , 2013, Leukemia.
[17] P. L. Bergsagel,et al. Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] D. Neuberg,et al. A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL , 2010, Leukemia.
[19] M. Calaminici,et al. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. , 2009, Blood.
[20] J. Gribben,et al. Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drug , 2009, Haematologica.
[21] Michael Hallek,et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. , 2008, Blood.
[22] Z. Estrov,et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. , 2008, Blood.
[23] Lisa L. Smith,et al. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Dan Zhu,et al. Immunomodulatory drugs Revlimid® (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation , 2008, Cancer Immunology, Immunotherapy.
[25] M. Czuczman,et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.